UFPT · UFP Technologies, Inc.

The thesis

UFP Technologies, a contract maker of medical-device components, has recovered to $300.7 (adjusted close, 2 October 2026) after its 18 September 2026 low close of $276.69. The recovery case now rests on the Q3 2026 report, estimated for about 2 November 2026, which has to show that Q2's 12.4% organic growth was not a one-quarter spike.

The prior note required a weekly close above $300 before a weekly close below $273. The week ended 2 October 2026 closed at $300.7, so that test has been met by a narrow margin. The narrative is maturing: the Q2 results are well known, the shares still sit 10.2% below the $334.84 52-week high, and the next test is the November report.

The operating record is stronger than the price history of the past month. The 3 August 2026 release reported Q2 sales of $174.0 million, up 15.1%, and organic growth of 12.4%. Q2 earnings release

Bullish and bearish views on UFP Technologies, Inc.

The bull case on UFP Technologies, Inc. (UFPT), in brief: Q2 beat expectations by a wide margin. The bear case: The rebound is sharp and stretched.

Bull case

• Q2 beat expectations by a wide margin. Benzinga reported on 3 August 2026 that adjusted earnings per share of $2.92 beat the $2.50 estimate, and sales of $173.964 million beat the $159.383 million estimate. The shares rose on 4 August 2026, when Benzinga listed UFPT among the day's gainers.
• Growth reached beyond the largest customers. The 3 August 2026 release reported Q2 growth of 14.7% among the top five customers and 19.7% across the rest of the medical-technology business. First-half organic growth was 6.8%, so Q2 marks a step up. Q2 earnings release
• An acquisition adds a printing capability. A company release dated 9 September 2026 announced CI Medical, which prints on difficult medical-device surfaces. No purchase price or acquired revenue was disclosed. Company release
• Price has recovered within two weeks. Adjusted daily closes show a rise from $276.69 on 18 September 2026 to $300.7 on 2 October 2026. The three-month price gain is 13.9% as of 2 October 2026.

Bear case

• The rebound is sharp and stretched. The 14-day relative strength index (RSI, a 0–100 momentum gauge) was 72.8 on 2 October 2026, against 20.4 on 18 September 2026. Readings above 70 are commonly described as overbought.
• Margin and capacity benefits are slower than planned. In the 3 August 2026 release, management said benefits from Dominican Republic investment were taking longer than anticipated and flagged near-term mix and margin pressure in US operations. Q2 gross margin was 29.3%. Management commentary
• A third-party target revision moved lower. Argus's quantitative report dated 9 September 2026 lowered its UFPT price target to $317. Argus report listing
• The company gives no annual guidance. UFP Technologies issues no forward revenue or earnings-per-share guidance, so the quarterly report is the only scheduled company update.

Price setup

The adjusted close on 2 October 2026 was $300.7. The 52-week high is $334.84, set earlier in the year, and the shares are 10.2% below it. The three-month price change is 13.9%.

The $300 level is the former trading range that held in early September and failed on 18 September 2026. The weekly close of $300.7 sits just above it, so a single weak week would put the shares back below it. The $273 level marks the intraday lows recorded on 15 September 2026 and 18 September 2026. A weekly close below it would show the September low giving way.

Crowding evidence is limited. The RSI reading of 72.8 points to short-term buying pressure, and the earnings date is about a month away. Analyst coverage is thin; no insider-selling or share-issuance filings were found for this period.

Catalysts, next 30 days

• ~2 November 2026, est. Q3 2026 results. MarketBeat's estimate; the company has not confirmed the date. Last year's Q3 release was filed 4 November 2025. The report tests whether organic growth holds above the 6.8% first-half rate and may disclose CI Medical's contribution.
• No other dated company events are scheduled inside the window.

What would change the view

The case breaks if the Q3 report shows organic growth falling back to or below the 6.8% first-half rate, or if gross margin falls below Q2's 29.3% with management pointing again to delayed Dominican Republic benefits. A weekly close below $273, under the September lows, would also end it. A weekly close above the $334.84 52-week high would strengthen the case.

What it trades with

UFPT trades on medical-device outsourcing demand and the spending of a small group of large customers. MedTech is its largest end-market, and top-five customer growth is disclosed as a separate line. Manufacturing in the Dominican Republic makes US tariff policy on imported medical components a recurring input to gross margin. Small-cap medical-device suppliers are the closest peers for price moves.